Clinical outcomes of pyrazinamide-monoresistant Mycobacterium tuberculosis in Quebec-Reference-Cited by-同舟云学术

Clinical outcomes of pyrazinamide-monoresistant Mycobacterium tuberculosis in Quebec

Published:2012-05-01 Issue:5 Volume:16 Page:604-609
ISSN:1027-3719
Container-title:The International Journal of Tuberculosis and Lung Disease
language:en
Short-container-title:int j tuberc lung dis

Author:

Yee D. P.¹,Menzies D.¹,Brassard P.²

Affiliation:

1. Respiratory Epidemiology and Clinical Research Unit, Montreal Chest Institute, McGill University Health Center, Montreal, Quebec, Canada

2. Division of Clinical Epidemiology, McGill University Health Center, Montreal, Quebec, Canada; Center for Clinical Epidemiology and Community Studies, Jewish General Hospital, Montreal, Quebec, Canada

Publisher

International Union Against Tuberculosis and Lung Disease

Subject

Infectious Diseases,Pulmonary and Respiratory Medicine

Cited by 19 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Chapitre 8: La tuberculose pharmacorésistante;Canadian Journal of Respiratory, Critical Care, and Sleep Medicine;2023-11-02

2. Insights from the molecular mechanism of pyrazinamide to mutated pyrazinamidase linked to the pncA gene in clinical isolates of Mycobacterium tuberculosis;Journal of Biomolecular Structure and Dynamics;2023-04-25

3. Designing molecular diagnostics for current tuberculosis drug regimens;Emerging Microbes & Infections;2023-02-27

4. Chapter 8: Drug-resistant tuberculosis;Canadian Journal of Respiratory, Critical Care, and Sleep Medicine;2022-03-24

5. A Case of Pulmonary Tuberculosis with Initial PZA Monoresistance Associated with Total Deletion of the <i>pncA </i>Gene;Kansenshogaku Zasshi;2021-07-20